BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
98 days-163 days |
18 |
median |
99.7 |
d |
4.38 |
18.6 |
necropsy |
0.0 |
0 |
two treatment |
fluorouracil 5-FU |
111143 |
3196 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
98 days-164 days |
18 |
median |
101.3 |
d |
3.87 |
16.4 |
necropsy |
0.0 |
0 |
two treatments |
5-fluorouracil + interleukin-2 |
111144 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-186 days |
21 |
|
9.5 |
% |
|
|
necropsy |
0.0 |
0 |
two treatments |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
111157 |
3196 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-162 days |
15 |
median |
98.7 |
d |
2.17 |
8.4 |
necropsy |
0.0 |
0 |
one treatment |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
111123 |
3196 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-146 days |
15 |
median |
82.7 |
d |
3.87 |
15.0 |
necropsy |
0.0 |
28 |
one treatment |
fluorouracil 5-FU |
111117 |
3196 |
BDIX/OrlCrl |
percentage of study population developing ascites during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-145 days |
15 |
|
100.0 |
% |
|
|
necropsy |
0.0 |
0 |
one treatment |
5-fluorouracil + thymosin alpha-1 |
111129 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-145 days |
15 |
|
87.0 |
% |
|
|
necropsy |
0.0 |
0 |
one treatment |
5-fluorouracil + thymosin alpha-1 |
111137 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-164 days |
18 |
|
22.0 |
% |
|
|
necropsy |
0.0 |
0 |
two treatments |
5-fluorouracil + interleukin-2 |
111156 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-157 days |
15 |
|
53.0 |
% |
|
|
necropsy |
0.0 |
0 |
one treatment |
5-fluorouracil + interleukin-2 |
111136 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-162 days |
15 |
|
13.0 |
% |
|
|
necropsy |
0.0 |
0 |
one treatment |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
111139 |
3196 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-157 days |
15 |
median |
94.0 |
d |
2.63 |
10.2 |
necropsy |
0.0 |
0 |
one treatment |
5-fluorouracil + interleukin-2 |
111120 |
3196 |
BDIX/OrlCrl |
percentage of study population developing ascites during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-157 days |
15 |
|
53.0 |
% |
|
|
necropsy |
0.0 |
0 |
one treatment |
5-fluorouracil + interleukin-2 |
111128 |
3196 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-145 days |
15 |
median |
81.7 |
d |
3.87 |
15.0 |
necropsy |
0.0 |
0 |
one treatment |
5-fluorouracil + thymosin alpha-1 |
111121 |
3196 |
BDIX/OrlCrl |
post-insult time of death due to metastatic liver tumors |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
98 days-186 days |
21 |
median |
122.6 |
d |
2.42 |
11.1 |
necropsy |
0.0 |
0 |
two treatments |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
111145 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-163 days |
18 |
|
89.0 |
% |
|
|
necropsy |
0.0 |
0 |
two treatment |
fluorouracil 5-FU |
111155 |
3196 |
BDIX/OrlCrl |
percentage of study population developing ascites during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-146 days |
15 |
|
100.0 |
% |
0.0 |
0.0 |
necropsy |
0.0 |
0 |
one treatment |
fluorouracil 5-FU |
111125 |
3196 |
BDIX/OrlCrl |
percentage of study population developing extra-hepatic metastases during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-146 days |
15 |
|
93.0 |
% |
|
|
necropsy |
0.0 |
0 |
one treatment |
fluorouracil 5-FU |
111133 |
3196 |
BDIX/OrlCrl |
percentage of study population developing ascites during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
peritoneum integrity trait |
male |
77 days-162 days |
15 |
|
13.0 |
% |
|
|
necropsy |
0.0 |
0 |
one treatment |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
111131 |
3196 |